Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Bonesupport, Audiocast with teleconference, Q3'24

By Inderes10/24/2024, 11:00 AM
Bonesupport

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Emil Billbäck
00:00 - 16:45

Welcome everyone to the BONESUPPORT third quarter 2024 results call. My name is Emil Billbäck, and I am making this broadcast as always, together with Håkan Johansson, our CFO, by my side. So we will use the next 25 minutes to guide you through the presentation of the third quarter results. And then we will open up the line for questions and answers. But before going through the presentation, we would like to draw your attention to the disclaimers covering any forward-looking statements that we will be making today. So let's start the presentation. Go to slide three. I would like to start the entire presentation with some condensed highlights from the report that we released this morning. So overall, quarter three sales results were at 238 million Swedish krona, which corresponds to a reported growth of over 50% year-over-year in constant exchange rate. The growth was 54%. The strong sales resulted in record operating results before incentive provisions. The operating results were 48 million Swedish kronor. The reported EBIT was at 41 million. The positive development resulted in a strong organic cash boost from 39 million SEK to 153 million SEK. Now, before moving into the details of the report, let me quickly cover the highlights of the quarter. The SOLARIO study has been running for more than four years, and hearing the positive outcome at a packed auditorium at the European Bone and Joint Infection Society's annual meeting was a personal milestone. Several leading representatives for the EBRD proclaimed that this is a game-changing study that will lead to modified treatment protocols. I will come back to the SOLARIO study later in the presentation. We're making good progress in our preparation for the Spinal Fusion market entry, and we will provide a short update and status in today's call. Finally, I would like to highlight that CERAMENT G in the US is taking significant market shares, reaching sales of 134 million SEK in the quarter. We continue to see that existing customers are continuously increasing their use and, in addition, new users are constantly being added. So, let's go into the presentation now and go to the next slide where we will look at sales development. This chart shows the last 12 months' sales in Swedish currency, every quarter since early 2017. In stacked bars per region and product category. In this slide, the strong launch momentum for CERAMENT G in the US is becoming very graphically visible. CERAMENT G in the US grew 114% year over year in the quarter, and the sales value of CERAMENT G in the US is now actually making up 50% of the total sales in the quarter. As we are broadcasting this, we are at the North American Orthopaedic Trauma Association meeting in Montreal, which is also coinciding with our launch conference for the open trauma indication. As CERAMENT G has only been market authorized for open trauma in the US since March of this year, we have not had close interactions with orthopedic trauma surgeons before. There are between 9,000 and 10,000 orthopaedic trauma surgeons in the US, and we expect to establish many new relationships at this Congress. For those interested in listening to some early experiences from CERAMENT G in trauma, I would recommend the podcast on BONESUPPORT's LinkedIn with three very prominent traumatologists sharing firsthand experiences of CERAMENT G. All in all, our top line is advancing with a solid and steep trajectory as CERAMENT G is rapidly taking market shares from other treatment options and is seemingly even expanding the market. The antibiotic-eluting segment is primarily driving the development, with a total 81% sales growth across the two regions in quarter three, 2024, compared to quarter three, 2023. Let's now move to North America on the next slide. Sales of 192 million SEK in the quarter correspond to a reported growth of 59% year over year and 63% at a constant exchange rate. Now, there were many highlights in the quarter. So in September, the NTAP reimbursement request for CERAMENT G in open trauma was submitted to CMS. The combination of easy handling, ability to perform a one-stage procedure, ability to mimic natural bone healing, and the release of local gentamicin over more than 30 days, appeals strongly to US surgeons and orthopedic clinics. These key points are the main reasons for the fast and substantial sales ramp-up. In addition, the avoidance of bone infection and the prevention of amputations are also incentivized through the regular US reimbursement system, which penalizes failed procedures or so-called modifier 78. That's the code for a failed procedure. The number of surgeons and nurses being trained on and using CERAMENT G is constantly increasing. We are progressing well with hospital system approvals, with a total of 145 listings for CERAMENT G at the end of quarter three. The focus right now is actually to strike a balance between adding hospital system approvals and training the surgeons and nurses in the hospitals where listing has been accomplished. We have to train each surgeon and nurse individually before using the product. A positive dynamic, though, is that surgeons who used CERAMENT G in 2023 and early 2024 have followed up on their patients and are sharing positive feedback and testimonials that they observe the same positive outcomes as those previously demonstrated in many published clinical studies on CERAMENT G. This gives a very positive endorsement, and we are receiving an increasing number of surgeon-to-surgeon referrals for CERAMENT G. So while we have been busy training surgeons for the last 23 months on CERAMENT G, we have only scratched the surface of the full opportunity. As an example, we have just surpassed 1,000 surgeons trained on CERAMENT G, and there are over 20,000 orthopedic surgeons in the US. Another interesting market dynamic that we would like to share with you is that approximately 10 to 15% of the surgeons who have started to use CERAMENT G in the last 12 months had previously not used any local antibiotics in their bone graft surgeries for extremities, as historically there were no FDA-approved alternatives. This is an early stage observation, but an interesting one, pointing towards CERAMENT G as a driver of market expansion. Several market investigations have shown that the use of local antibiotics in Europe is estimated to be almost ten percentage points higher than in the US. But possibly, we are seeing some initial tendencies of the US moving in the European direction. And finally, a few mentions on our preparations for the future entry in the spinal fusion segment. So in preparing for the market entry into spinal fusion, we have conducted several different activities to further map the market dynamics and determining factors for surgeons' choice of technique and material. Overall, what we derive from market insights is that a large portion of surgeons have concerns regarding infections during and after spinal fusion surgeries; 57% of these surgeons consider infection following the surgery to be a significant clinical issue. The use of local antibiotics has become an unregulated and off-label standard of care, used in between 35% to 40% of all spinal fusion procedures, and we are making good progress in running several preclinical studies to build applications, instructions, and handling manuals for the various techniques in spinal fusion. And we hope to share some initial data from these at the quarter four report in February next year. But now let's turn to Europe and the rest of the world. So for the quarter, we saw sales of 46 million SEK, corresponding to a reported growth of 22% year over year and 21% at a constant exchange rate. We are seeing good progress in Europe, where sentiment is capturing market shares in more or less all markets where present. However, there was a higher than expected negative seasonality impact in quarter three, which was exacerbated by healthcare staffing disruptions in many areas. This resulted in fewer surgeries overall compared to the previous quarter, as well as slightly challenging market access for our sales representatives. Looking at this quarter's highlight, CERAMENT V was approved for market introduction in Canada, and CERAMENT G is already being sold in Canada through distributors. The business is developing well with the addition next year of CERAMENT V. We believe that the market potential will increase further, and we have therefore decided to mirror the successful implementation in Spain and Italy. And we are now recruiting to also transform Canada into a hybrid market with both distributor representatives and our own staff on the ground. The largest highlight is, of course, that the SOLARIO study met its primary endpoint, showing that bone substitutes with local antibiotics enable reduced systemic antibiotic treatment. Let's go a bit more in detail into this SOLARIO study. Being able to reduce systemic antibiotics by using CERAMENT G or V could have a profound effect on the fight against antibiotic resistance, as well as significantly reduce the challenging side effects associated with systemic antibiotic treatment. This is why this study is so important. Only top line results from the SOLARIO study have been released so far, so we should expect the full-length article to be published sometime next year, upon which we will have more data and details about adverse events and the full cost analysis. However, based on what we've learned from the top-line results, these results are indeed spectacular. The standard protocol around the world for a patient with a bone infection is to administer more than four weeks of systemic antibiotics, and often, this treatment will last and continue for 6 to 8 weeks. Healthcare practitioners are well aware of the difficult side effects and the high cost of this treatment, but it has been seen as a necessary evil to manage the bone infection. The SOLARIO study challenges the existing protocols, as it shows that antibiotic-eluting bone fillers enable systemic antibiotic treatment for less than a week, without any increase in the reinfection rate. This has a significant and material effect on the side effects, as visible in the graph to the right. It should be mentioned that these adverse events and side effects are in no way trivial. They are causing significant patient suffering and societal costs. Severe events. Severe adverse events in the study were classified as life-threatening or requiring hospitalization, or resulting in persistent or significant disability. To further understand the seriousness of the adverse events, treating an episode of nephrotoxicity, which affects between 5% to 20% of patients on long-term vancomycin treatment, could easily cost up to $15,000. We know also, from protocol and available data, that one week of intravenous antibiotic combination treatment costs up to $3,500 USD in the US and around £1,600 in the UK. If we take a US reimbursement perspective on treatment failures and adverse events. So if these happen within 30 days after the index surgery, they are categorized as failures, which is also called modifier 78. The reimbursement for the follow-on treatment of the patient then drops by 20 to 30%. Antimicrobial Resistance is one of the greatest public health and development threats. The misuse and overuse of antimicrobials in humans, animals, and agriculture are the main contributors to the rise of drug-resistant pathogens. According to the Antimicrobial Resistance Review report, by 2050, as many as ten million people could die each year due to antimicrobial resistance, and the World Bank has estimated that enormous costs will be associated with antimicrobial resistance. So on that rather apocalyptic and dramatic note, I would like to hand over to Håkan Johansson. Thank you, Emil. So let's move to slide number nine.

Håkan Johansson
16:45 - 20:29

Net sales improved from 158.2 million to 237.5 million, equalling a growth of 50%, or 54% in constant exchange rates. Emil has already spoken about the strong performance and the major drivers behind the sales acceleration. The contribution from the North America segment improved by 32.8 million and amounted to 79.3 million. The improved contribution relates to increased sales offsetting the effect of higher costs. Sales and marketing expenses during the quarter amounted to 102 million, compared with 67.6 million in the previous year, of which sales commissions to distributors and fees amounted to 65 million, compared with 42.2 million in the same quarter last year. From the lower graph showing net sales as bars and gross margin as the orange marker. It can be noted that the gross margin remained strong, amounting to 94.7%. The drop from the second quarter this year. All in all, this relates to a weaker US dollar in Europe and the rest of the world. A contribution of 15.6 million was reported compared with 9.3 million the previous year. Sales and marketing expenses increased slightly, with a minor drop of 0.3 million compared with the second quarter this year, following seasonality depicted in the lower graph and the orange market. You can see the gross margin remaining stable. The increase in selling expenses reflects investments in the organization, but also investments in systems to improve customer handling and inventory management to stay ahead of the increasing demand. The slight reduction compared with the second quarter this year follows normal seasonality, as presented at our Capital Markets Day in November. R&D is focused on the execution of strategic initiatives such as spinal fusion and a planned market authorization submission for CERAMENT V in the US. These initiatives have been progressing well during the quarter, which also explains the increasing spend on administration expenses. Excluding the effects from the long-term incentive programs, levels remain stable. However, this was impacted in the period by temporary resources in the quarter. To sum up the financials, the reported operating profit amounted to 41 million, an improvement of 26.1 million compared with the same quarter last year. This follows a strong sales performance despite unfavorable currency effects in the period and despite the investments made in our commercial platform and innovation. The difference between adjusted EBIT and reported EBIT. Operating results show our costs regarding our long-term incentive programs, amounting to an expense of $7.3 million in the quarter, compared with $9.7 million the previous year. As you can see from the previous slide, of the total cost of 7.3 million in the period, only 1.9 million was cash flow, impacting with strong momentum our sales increase and safety. Stocks of raw materials and semi-finished products were purchased during the first half of this year. As we have now reached satisfactory levels of inventories, we see a strong cash flow returning, improving cash balance with 39 million during the quarter. So with this, I hand it back to Emil.

Emil Billbäck
20:30 - 21:20

Yeah, thank you very much. And we're going to conclude this presentation now. We're of course, very pleased with the quarterly performance and the continuous solid trend. All three quarters in 2024 have shown sales growth well above 50%. And we see solid and robust sales trending over the past 24 months. The current market penetration is strong, and we anticipate further future sales enablers to play out, with a milestone being the SOLARIO study, the entry of CERAMENT G in open trauma, and the future entry into the spinal fusion segment, thanks to its clinical superiority over standard of care. CERAMENT V is constantly increasing its user base.

Unknown 1
21:20 - 21:21

And.

Emil Billbäck
21:21 - 21:30

Enabling surgeons to achieve better patient outcomes. With that, we close our presentation and we'd like to open the line for questions.

Operator
21:35 - 21:56

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Matthias Waddesdon from Carnegie Investment Bank. Please go ahead.

Matthias Waddesdon
21:59 - 22:37

Yes. Hi, Emil. Thanks for taking my questions. I have some questions here related to the SOLARIO study to begin with. I think there are ample reasons. The goal is to lower the use of systemic antibiotics and instead use CERAMENT G and V. We also know that changes are slow out there, especially in Europe. And I think you talked about treatment protocol changes here in the presentation. But what can you share in terms of the speed at which behaviors will change, and maybe also comment on some of the dynamics in the US for a bit as well? That's the first one.

Unknown 1
22:38 - 22:39

Thank you.

Emil Billbäck
22:39 - 25:39

Thank you, Matthias, and thanks for joining us today. Yes, unfortunately, I'm probably not well positioned to speak about speed because when I joined BONESUPPORT and discovered this great technology, I thought the success would come even faster. But eventually results came and it's difficult to predict how much time it will take this time to actually change old behaviors in a rather conservative customer group. You mentioned also a difference between us and Europe. I believe this change will be facilitated. Of the fact that the study is not our study. It is the study of the European Bone and Joint Infections Society, which has members all across Europe and also some in the US. The second point, I think there is a general trend which is communicated also as a wanted direction by the United Nations and the W.H.O. To have a more balanced use of antibiotics as the current path is unsustainable, so a change is demanded. And lastly, what we see, Matthias, many times in the US, is that they are slightly faster to jump on topics with strong clinical and scientific evidence if it also has a financial impact on the healthcare system. So they care most about the patient, of course, but they also have a more monetary consciousness. And I believe that there is not a single orthopedic surgeon who has not experienced patient suffering, and also the financial impact of a patient returning with nephrotoxicity, hearing loss, or red man syndrome, which has also cost large amounts to treat these adverse events. No one had really taken the strong initiative to reduce the use of systemic antibiotics before, because there was no data and no one wanted to be the first to do it and risk facing setbacks. Now there is data from one of the largest published studies in this domain. So hopefully these are levers that will justify a faster change of protocols than what we have seen historically, because historically it has been a bit discouraging to see how slow these protocols change.

Matthias Waddesdon
25:44 - 26:09

Thanks so much for that. I appreciate it's a difficult question, but good answer. And I think secondly, this has been well addressed in the discussion as well. Local antibiotics are used in 38% of extremity surgeries with bone grafts in the US and 47% in Europe, according to this analysis. And an even tougher question then: What share of your market, in your view, should focus on robotics, say, in the long term?

Unknown 1
26:11 - 26:14

I think the number is going to.

Emil Billbäck
26:14 - 26:46

Rise both in Europe and in the US. Um, we see that there's constantly a trend away from autografts to more synthetic grafts. And given the overwhelming evidence available now, including the SOLARIO study, I wouldn't be surprised if the use of local antibiotics as a first step will go up to 60% of the procedures but could potentially continue after that.

Matthias Waddesdon
26:50 - 27:27

Thanks so much for that. I will limit myself to one more question before jumping back to the queue. It would be great to hear you talk a bit about the performance of early adopters and initial customers in the US. And if you could give a feel for how sticky the customer base is, it seems very sticky. And how much stop-and-go are you experiencing right now. And also, maybe the typical question of commenting a little bit on growth that you see coming from previous customers and the share that is coming from incremental new customers. That's my last one for now.

Unknown 1
27:28 - 27:29

Yep.

Emil Billbäck
27:29 - 28:07

We are fortunate to work with a fantastic product. We are unfortunate in that we are in a dynamic where initially, during surgery, one can only assess the handling and applicability of the product. It takes 3 to 6 months before we get the final verdict, and we receive SMSes, WhatsApp messages, or emails from the surgeon saying, "Wow, I have achieved great results."

Unknown 1
28:07 - 28:09

So there's a time lag.

Emil Billbäck
28:09 - 29:06

And we know that if we lose a surgeon who has started to use CERAMENT G and they stop using it, it is in the first six months before they have seen the final results of the bone remodeling, and they've seen that the patient is infection-free for the entire treatment period. What is also an interesting dynamic here now is that those surgeons who are very meticulous and have followed up with their patients, as well as documented their observations, see almost the same results as the well-controlled studies conducted in both the US and Europe. So if the product works, it doesn't only work in the hands of prominent surgeons in university hospitals, it also works with the common orthopedic surgeon struggling.

Unknown 1
29:06 - 29:06

With.

Emil Billbäck
29:06 - 30:00

Challenging indications day to day. And the dynamic also is such that no one will use a new product like this before they have been trained. So even though a lot of people have now read about the SOLARIO study, it is sending shockwaves, I would say, around the world, and people are becoming aware of it. People will not start using CERAMENT G until they have received the necessary training. So it's rather tiresome work. And I mentioned in the call that we've trained a bit more than 1,000 surgeons out of 20,000, so it can feel like an almost endless journey. But we know that the ones who have been trained and are using it, the loyalty to the product and to producing better patient outcomes is very high. So we feel very confident and energetic on this journey going forward.

Matthias Waddesdon
30:04 - 30:05

Thanks so much.

Operator
30:12 - 30:17

The next question comes from Christopher Liljeberg from Carnegie Investment Bank AB. Please go ahead.

Christopher Liljeberg
30:21 - 31:34

Thank you, and good morning to you, too. In the US, I have four questions. Uh, try to be shorter, but the first one is the first question. SOLARIO. So, are all the patients receiving systemic antibiotics typically treated intravenously, or could it also be oral? Because you mentioned the cost of treating with intravenous antibiotics, and then moved on to, um, the proportion of patients that receive local treatment with antibiotics. Was that for extremities overall, or do you know what the figures for bone infection, specifically those related to SOLARIO, are? And then, just a question regarding working capital as a percentage of sales, where do you think that will be over time? It has fluctuated a bit here, up and down, early in the launch. I just wonder about the NTAP or actually the outpatient segment. How much is that contributing to growth? Uh, now. Thank you.

Unknown 1
31:36 - 31:36

Yeah, thank you.

Emil Billbäck
31:36 - 31:48

Very much, Christopher. Um, there was a little bit of distortion on the line when you asked the first question. I actually could not hear the full context. I don't know if you heard it. Could you help me, or otherwise? We have to hear it again.

Håkan Johansson
31:48 - 31:55

The first question was on how the antibiotics were distributed to the patients. Well, if it was all intravenous, or something else.

Emil Billbäck
31:55 - 31:56

In the SOLARIO study.

Håkan Johansson
31:56 - 31:56

Study.

Unknown 1
31:57 - 31:57

Yeah.

Emil Billbäck
31:57 - 32:00

No, we don't know that yet. Actually, we have the.

Unknown 2
32:00 - 32:02

We specifically asked the group.

Emil Billbäck
32:03 - 33:14

On how much was intravenous and how much was per oral, and the team conducting the study has let us know that this data will come in the full presentation. So we don't have the data. We know that vancomycin was one of the most used antibiotics, and vancomycin is given almost always intravenously. We also know that there is a higher degree of intravenous treatment in the first couple of weeks in the long arm. We also know that, due to severe side effects and some of those failures, the patients have been hospitalized and received intravenous treatment. But more than that, we don't know. So this will have to be for further and future analysis. Uh, the next question was regarding the use of antibiotics in extremities. So I presume here that you refer to slide five in the presentation, the 38% that we saw.

Christopher Liljeberg
33:14 - 33:29

Saw from it. Yeah. Sorry. So the question was actually about patients with bone infections. I guess that figure is higher than for all extremities.

Unknown 1
33:29 - 33:31

Yes, yes, we know what that figure is today.

Christopher Liljeberg
33:31 - 33:33

Yes, we know what that figure is today.

Emil Billbäck
33:34 - 33:37

I would say it's close to 100%. It could be.

Unknown 1
33:38 - 33:39

Yeah.

Emil Billbäck
33:40 - 33:45

A few percentage points deviate, but almost 100% of patients with bone infections.

Unknown 1
33:45 - 33:45

And.

Emil Billbäck
33:45 - 33:48

Active bone infections are receiving local antibiotics today.

Christopher Liljeberg
33:51 - 34:03

Okay. But if that is the case, how will the SOLARIO study address this? Increased use of serum if all patients are already receiving low-dose antibiotics today.

Unknown 1
34:06 - 34:07

I think.

Emil Billbäck
34:07 - 34:27

SOLARIO is a great study in that it shows one of the most challenging conditions of bone infection and an antibiotic course which, according to SOLARIO, is too short if it lasts less than four weeks. So the greatest effect of the SOLARIO study is that.

Unknown 1
34:27 - 34:29

The.

Emil Billbäck
34:29 - 35:33

Systemic antibiotic use can be shortened with the regular use of an antibiotic-eluting bone graft. But in many of these patients, specifically in the US, vancomycin powder is being used, sprinkled directly into the bone. Infection. No such patients were included in the SOLARIO. There's also a lot of off-label mixing with very dubious results. None of those were included in the SOLARIO study, so if you want to make sure that you treat the patient in the best possible way, and you want to ensure that you comply with the scrutiny of the FDA, and you would like to have the ability to reduce your systemic antibiotic use, then you need to use a product that has been regulatorily approved and has been part of the largest clinical study. So that is how I see that more patients will receive CERAMENT G and V going forward.

Unknown 1
35:35 - 35:35

Okay.

Christopher Liljeberg
35:35 - 35:36

That makes a lot of sense. Thank you.

Emil Billbäck
35:38 - 35:39

So, just to clarify.

Unknown 1
35:39 - 35:42

To follow up there, Christopher, we saw that.

Emil Billbäck
35:42 - 36:11

As an example, of all the patients in the US where local antibiotics were used in bone infections. Um, 40% used PMMA beads, where we know that the reinfection rate is around 13%. With CERAMENT G and V, the reinfection rate is down to 5%. So. So, yes, it's local antibiotics, but there are significant differences in results.

Unknown 1
36:15 - 36:15

Thank you.

Håkan Johansson
36:19 - 37:00

Your next question was about the working capital. And it's correct. Now reporting a plus 50% growth and strong sales momentum. . It tends to create a certain volatility in working capital ratios relative to sales. And we haven't set a firm long-term target. But some are just looking at the numbers and how it looks over time. It is reasonable to believe that it should be able to land somewhere between 22 and 24% in relation to annualized sales.

Unknown 1
37:09 - 37:10

Okay.

Operator
37:10 - 37:15

Any further questions come from Maria Vara from Bryan Garnier. Please go ahead.

Maria Vara
37:19 - 38:04

Hi, Emil. Håkan, thank you for the presentation and congratulations on the great traction in the US with CERAMENT G. I just want to touch upon the development of spinal fusion and provide some remarks and insights on how CERAMENT G is gaining traction in the US due to the need for. Same way in spinal fusion. Would it be, you know, more strategic or actually necessary to accelerate antibiotic approval for the spine? Yes. It's my belief that initially you will go to market with IVF, which of course will be useful for bone graft applications alone. But, you know, if you could give a bit of insight into how you plan on proceeding.

Unknown 1
38:07 - 38:08

Yeah. Thank you.

Emil Billbäck
38:08 - 39:46

Maria, thanks for being with us. So, again, a bit of disruption on the line, but we'll try to provide a good answer. Yeah. Of course, when we discuss the matter with spinal surgeons or neurologists, the first question that comes up is when can we have CERAMENT G. So you picked the dynamics perfectly there, Maria. And the data that we have on bone void filler in this perspective is more extensive. So, we will have to initiate data development to apply for CERAMENT G to achieve approved indications for spinal fusion. When that happens, we will announce it to the market. We will let the market know when we have made the decision to go forward and the work we're doing now on CERAMENT V. VF is also laying the foundation for CERAMENT G in spine. We are learning valuable insights on how the product should be applied. As an example, the most common procedure on the spine is Interbody fusion. It represents between 75 and 80% of all spinal fusions. And for interbody fusion, there are five different techniques that can be used and several different variants. So we are now testing how CERAMENT G, as one of the very few.

Unknown 1
39:46 - 39:47

Few.

Emil Billbäck
39:47 - 40:22

Injectable products can be applied using a convincing technique. And we're also monitoring and tracking bone remodeling and bone growth. And how is the product resorbed in this new indication. So all that data can also be used for our ultimate project, which is of course to bring CERAMENT G into spinal fusion. And that's all I can say. Now we will come back with the timing. We're working hard on it. That is what I can promise.

Maria Vara
40:27 - 40:29

All right. Thank you. That's all from my side.

Operator
40:37 - 40:42

The next question comes from Sten Gustafsson from ABG Sundal Collier AB. Please go ahead.

Unknown 1
40:45 - 40:45

Yes.

Sten Gustafsson
40:45 - 41:30

Hi. Good morning. Uh, first question. CERAMENT G in the U.S. It's a pretty significant step change, a sort of sequential uplift in sales in the third quarter. So my first question is, are you aware of any sort of inventory buildup among customers, or are there any extraordinary sales reported during the quarter? Or is this just a change in the trajectory?

Unknown 1
41:33 - 41:35

Yes. Thank you. Sten. No, we are very pleased, of course, with the strong performance in the quarter.

Emil Billbäck
41:35 - 43:37

We are very pleased, of course, with the strong performance in the quarter. And we have analyzed and gone through the numbers and I can confirm there are no inventory builds. There are no one-off orders. There are no bulk orders. That is behind these sales. The end. Well, the extraordinary thing that I can mention is hard work. And we have had especially strong success in California. And we're making great inroads in Florida, both of which are notoriously big orthopedic markets, and in regions where we've had lower penetration before, such as New Jersey and New York. Sales are taking off very nicely. But I should also be humble and say that we have declared that there will be a 'go, stop, go' behavior. Uh, and it's puzzling that we haven't seen any such disruption. So far, the curve has been almost linear for CERAMENT G. We're very happy with that, of course, but we're also experienced in the game, and we know that one day there will be a disruption when a larger hospital chain has its usage stopped by procurement. This is when we must rush in with our health economic data, where we now also have SOLARIO, of course, which will be strong, but disruptions will still occur. But I have to conclude that so far there is not a single hospital system or hospital that has paused CERAMENT G and has not continued to use it after we have discussed the data, so there could be temporary disruptions back and forth. But the long-term trend, I think you should all feel very confident with.

Sten Gustafsson
43:39 - 44:16

Yeah. No, thank you. Thanks for that. Um, and I mean, in theory, you could almost argue that the incremental growth in SEK should go up even more now, when you target a broader audience with the trauma surgeons going forward. So, my question would be, do you expect an even higher incremental sales growth going forward?

Unknown 1
44:18 - 44:19

So yeah, and.

Emil Billbäck
44:19 - 45:28

I also realized that I had received a question earlier about the TPT and the outpatient setting. If we are seeing sales pick up there. So, what we know, and everyone else here understands, is that movements in orthopedics are slow. It's a hands-on process. It's the ramp-up that takes time. We have started to see some outpatient setting sales in quarter three. We have seen a few orthopedic surgeons come on board, using the product for open trauma. But these are rather vectors for the future. So we don't give forecasts for the next quarter or the quarter after. But I can tell you that all of you, with the questions you're raising, you have fully understood the dynamics and the opportunities in trauma, outpatient settings; these are market segments that have opened up where we previously had no sales. And these will continue to increase going forward.

Sten Gustafsson
45:32 - 46:05

Great. Um, and then one question on the spine opportunity here. You received questions earlier about CERAMENT G and its application in the spine. Have you considered using CERAMENT V in spine? I'm not an expert on this, but someone told me that the kind of infections related to the spine could be perhaps more relevant for CERAMENT V. Um, is that something you have considered?

Unknown 1
46:06 - 46:07

Yes, we have.

Emil Billbäck
46:07 - 47:10

We have also considered CERAMENT V for spine applications. And there are different pathogens that can infect a wound and that can make it into the bone. Different antibiotics work for various pathogens. But gentamicin is broad-spectrum and has very good coverage of the potential microbes that would represent the infestation. CERAMENT V is mainly used when there is methicillin-resistant bacteria. Um, so it’s a good complement and supplement. And then there are different preferences around the world. So our position is not to try to make a distinction here, but rather say we will have two products available in the case there are resistant bacteria and in case there are certain preferences in some direction.

Unknown 1
47:13 - 47:13

Okay.

Sten Gustafsson
47:14 - 47:18

Thank you very much. I'll get back in the queue. Thank you.

Unknown 1
47:19 - 47:19

Thank you.

Operator
47:24 - 47:30

The next question comes from Christopher Liljeberg from Carnegie Investment Bank AB. Please go ahead.

Unknown 3
47:33 - 47:34

Yes.

Christopher Liljeberg
47:34 - 48:05

This was actually to remind you about my last question, but you answered that. But another thing I wonder, and now we're launching trauma, etc. What capability do you have to train a large number of surgeons? Do you continue to add sales representatives through your external distributors, and how does that compare with the number of feet on the ground versus a couple of quarters ago?

Unknown 1
48:05 - 48:07

Yes. Uh, it's.

Emil Billbäck
48:07 - 49:16

Definitely a good question. We are increasing the number of distributors. We're increasing the number of salespeople. We now have around 430 sales reps on the ground. And many of the distributor reps that we're working with are very good and have relationships with all the different subspecialties at the orthopedic clinic. So when they come and visit the hospital, they might go to one orthopedic surgeon covering one part of the body. Then they go to the next one after that. Being a traumatologist, before they leave the hospital, they might even go down to the spine surgeon. So many times it can be covered by the same sales reps on the ground. But to be more specific, we have also signed up specific distributors that are focused on trauma and have specific trauma hardware in their portfolio, and they've been very pleased to add CERAMENT G to their value proposition.

Christopher Liljeberg
49:20 - 49:21

Great. Thank you.

Emil Billbäck
49:24 - 49:25

Thank you, Christopher.

Operator
49:27 - 49:33

As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad.

Unknown 3
49:47 - 49:48

Well.

Emil Billbäck
49:49 - 49:52

It doesn't look like there are more questions.

Unknown 1
49:52 - 49:53

There are no more.

Operator
49:53 - 50:03

There are no more questions from the phone lines at this time. So I hand the conference back to the speakers for any written questions and closing comments. Please go ahead.

Unknown 1
50:03 - 50:04

Yeah. You know.

Emil Billbäck
50:04 - 50:27

I just want to thank everyone for taking the time to listen to our presentation of the quarterly report. Håkan and I will now move out. Håkan and I will now have a quick breakfast with coffee before we head back into the congress area to spread the word about CERAMENT G with the orthopedic traumatologist. So thank you, everyone, and take care. Bye bye.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…